Cartesian Therapeutics Inc. (RNAC)
| Market Cap | 135.20M |
| Revenue (ttm) | 34.53M |
| Net Income (ttm) | -36.16M |
| Shares Out | 154.80M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | 25.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 695,971 |
| Open | 0.720 |
| Previous Close | 0.740 |
| Day's Range | 0.680 - 0.750 |
| 52-Week Range | 0.660 - 1.990 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2023 |
About RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, inc... [Read more]
Financial Performance
Financial StatementsNews
Selecta Biosciences Announces Merger with Cartesian Therapeutics
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease –
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therap...
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 –
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo ...
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023...
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic thera...
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLV...
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLV...
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 -
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therap...
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therap...
Selecta Biosciences Provides Business Update and Outlook for 2023
- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 -
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M...
Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program
– IgA protease candidate in combination with ImmTOR further enhances pipeline –
Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therap...
Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platfo...
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 –
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platfo...
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
Data to be featured in one poster and two oral presentations Data to be featured in one poster and two oral presentations
Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platf...
Selecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera...
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera...
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline ...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therap...
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therap...